Potentiation of excitotoxicity in HIV-1-associated Dementia and the significance of glutaminase

Clinical Neuroscience Research

Volumn 6, Issue 5, 2006, Pages 315-328

  Erdmann, Nathan B ^a,b   Whitney, Nicholas P ^a,b   Zheng, Jialin ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Excitotoxicity; Glutamate; Glutaminase; HIV 1 associated dementia; Macrophage; Neurodegeneration

Indexed keywords

ANTIRETROVIRUS AGENT; GLUTAMATE RECEPTOR; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; GLUTAMINASE; GLUTAMINE; PHOSPHATE;

AMINO ACID SYNTHESIS; ARTICLE; ASTROCYTE; CENTRAL NERVOUS SYSTEM; DEMENTIA; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME ACTIVATION; ENZYME ACTIVITY; EXCITOTOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MACROPHAGE; NERVE CELL; NERVE CELL LESION; NERVE DEGENERATION; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR UPREGULATION;

EID: 33845214060     PISSN: 15662772     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cnr.2006.09.009     Document Type: Article

References (196)

1. Piot P., Bartos M., Ghys P.D., Walker N., and Schwartlander B. The global impact of HIV/AIDS. Nature 410 6831 (2001) 968-973
2. McArthur J.C. Neurologic manifestations of AIDS. Medicine (Baltimore) 66 6 (1987) 407-437
3. McArthur J.C., Hoover D.R., Bacellar H., Miller E.N., Cohen B.A., Becker J.T., et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 43 11 (1993) 2245-2252
4. Michaels J., Sharer L.R., and Epstein L.G. Human immunodeficiency virus type 1 (HIV-1) infection of the nervous system: a review. Immunodefic Rev 1 1 (1988) 71-104
5. Koenig S., Gendelman H.E., Orenstein J.M., Canto M.C.D., Pezeshkpour G.H., Yungbluth M., et al. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233 4768 (1986) 1089-1093
6. Gabuzda D.H., Ho D.D., Monte M.S.D.L., Rota T.R., and Sobel R.A. Immunohistochemical identification of HTLV-III antigen in brains of patients with AIDS. Ann Neurol 20 (1986) 289-295
7. Wiley C.A., Schrier R.D., Nelson J.A., Lampert P.W., and Oldstone M.B.A. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci USA 83 (1986) 7089-7093
8. Navia B.A., Jordan B.D., and Price R.W. The AIDS dementia complex: I. Clinical features. Ann Neurol 19 (1986) 517-524
9. Dore G.J., Hoy J.F., Mallal S.A., Li Y., Mijch A.M., French M.A., et al. Trends in incidence of AIDS illnesses in Australia from 1983 to 1994: the Australian AIDS cohort. J Acquir Immune Defic Syndr Hum Retrovirol 16 1 (1997) 39-43
10. Sacktor N., Lyles R.H., Skolasky R., Kleeberger C., Selnes O.A., Miller E.N., et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 56 2 (2001) 257-260
11. Janssen R.S., Saykin A.J., Cannon L., Campbell J., Pinsky P.F., Hessol N.A., et al. Neurological and neuropsychological manifestations of HIV-1 infection: association with AIDS-related complex but not asymptomatic HIV-1 infection. Ann Neurol 26 5 (1989) 592-600
12. Sacktor N., McDermott M.P., Marder K., Schifitto G., Selnes O.A., McArthur J.C., et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 8 2 (2002) 136-142
13. Ellis R.J., Deutsch R., Heaton R.K., Marcotte T.D., McCutchan J.A., Nelson J.A., et al. Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch Neurol 54 4 (1997) 416-424
14. Cherner M., Masliah E., Ellis R.J., Marcotte T.D., Moore D.J., Grant I., et al. Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 59 10 (2002) 1563-1567
15. Ryan L.A., Cotter R.L., Zink W.E., Gendelman H.E., and Zheng J. Macrophages, Chemokines and Neuronal Injury in HIV-1 Associated Dementia. Cell Mol Biol 48 2 (2002) 125-138
16. Belmadani A., Zou J., Schipma M.J., Neafsey E.J., and Collins M.A. Ethanol pre-exposure suppresses HIV-1 glycoprotein 120-induced neuronal degeneration by abrogating endogenous glutamate/Ca(2+)-mediated neurotoxicity. Neuroscience 104 3 (2001) 769-781
17. Zink W.E., Zheng J., Persidsky Y., Poluektova L., and Gendelman H.E. The neuropathogenesis of HIV-1 infection. FEMS Immunol Med Microbiol 26 3-4 (1999) 233-241
18. Giulian D., Wendt E., Vaca K., and Noonan C.A. The envelope glycoprotein of human immunodeficiency virus type 1 stimulates release of neurotoxins from monocytes. Proc Natl Acad Sci USA 90 7 (1993) 2769-2773
19. Pulliam L., Clarke J.A., McGuire D., and McGrath M.S. Investigation of HIV-infected macrophage neurotoxin production from patients with AIDS dementia. Adv Neuroimmunol 4 3 (1994) 195-198
20. Jiang Z., Piggee C., Heyes M.P., Murphy C., Quearry B., Bauer M., et al. Glutamate is a mediator of neurotoxicity in secretions of activated HIV- 1-infected macrophages. J Neuroimmunol 117 1-2 (2001) 97-107
21. Cutler R.W., and Dudzinski D.S. Regional changes in amino acid content in developing rat brain. J Neurochem 23 5 (1974) 1005-1009
22. Fonnum F. Glutamate: a neurotransmitter in mammalian brain. J Neurochem 42 1 (1984) 1-11
23. Orrego F., and Villanueva S. The chemical nature of the main central excitatory transmitter: a critical appraisal based upon release studies and synaptic vesicle localization. Neuroscience 56 3 (1993) 539-555
24. Olney J.W. Glutamate-induced neuronal necrosis in the infant mouse hypothalamus. An electron microscopic study. J Neuropathol Exp Neurol 30 1 (1971) 75-90
25. McCall A., Glaeser B.S., Millington W., and Wurtman R.J. Monosodium glutamate neurotoxicity, hyperosmolarity, and blood-brain barrier dysfunction. Neurobehav Toxicol 1 4 (1979) 279-283
26. Choi D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1 8 (1988) 623-634
27. Newcomb R., Sun X., Taylor L., Curthoys N., and Giffard R.G. Increased production of extracellular glutamate by the mitochondrial glutaminase following neuronal death. J Biol Chem 272 17 (1997) 11276-11282
28. Ollenschlager G., Jansen S., Schindler J., Rasokat H., Schrappe-Bacher M., and Roth E. Plasma amino acid pattern of patients with HIV infection. Clin Chem 34 9 (1988) 1787-1789
29. Droge W., Eck H.P., Betzler M., and Naher H. Elevated plasma glutamate levels in colorectal carcinoma patients and in patients with acquired immunodeficiency syndrome (AIDS). Immunobiology 174 4-5 (1987) 473-479
30. Zhao J., Lopez A.L., Erichsen D., Herek S., Cotter R.L., Curthoys N.P., et al. Mitochondrial glutaminase enhances extracellular glutamate production in HIV-1-infected macrophages: linkage to HIV-1 associated dementia. J Neurochem 88 1 (2004) 169-180
31. Wurdig S., and Kugler P. Histochemistry of glutamate metabolizing enzymes in the rat cerebellar cortex. Neurosci Lett 130 2 (1991) 165-168
32. Nicklas W.J., Zeevalk G., and Hyndman A. Interactions between neurons and glia in glutamate/glutamine compartmentation. Biochem Soc Trans 15 2 (1987) 208-210
33. Ward H.K., Thanki C.M., and Bradford H.F. Glutamine and glucose as precursors of transmitter amino acids: ex vivo studies. J Neurochem 40 3 (1983) 855-860
34. Curthoys N.P., and Watford M. Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr 15 (1995) 133-159
35. Kvamme E., Svenneby G., Hertz L., and Schousboe A. Properties of phosphate activated glutaminase in astrocytes cultured from mouse brain. Neurochem Res 7 6 (1982) 761-770
36. Holcomb T., Taylor L., Trohkimoinen J., and Curthoys N.P. Isolation, characterization and expression of a human brain mitochondrial glutaminase cDNA. Brain Res Mol Brain Res 76 1 (2000) 56-63
37. Lipton S.A., and Gendelman H.E. Dementia associated with the acquired immunodeficiency syndrome. New Engl J Med 16 (1995) 934-940
38. Shi B., Girolami U.D., He J., Wang S., Lorenzo A., Busciglio J., et al. Apoptosis induced by HIV-1 infection of the central nervous system. J Clin Invest 98 9 (1996) 1979-1990
39. Nath A., Conant K., Chen P., Scott C., and Major E.O. Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon. J Biol Chem 274 24 (1999) 17098-170102
40. Kaul M., Garden G.A., and Lipton S.A. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410 6831 (2001) 988-994
41. Vitkovic L., da Cunha A., and Tyor W.R. Cytokine expression and pathogenesis in AIDS brain. Res Publ Assoc Res Nerv Ment Dis 72 (1994) 203-222
42. Wesselingh S.L., Power C., Glass J.D., et al. Intracerebral cytokine messenger RNA expression in acquired immune deficiency syndrome dementia. Ann Neurol 33 (1993) 576-582
43. Nuovo G., and Alfieri M. AIDS dementia is associated with massive, activated HIV-1 infection and concomitant expression of several cytokines. Mol Med 2 (1996) 358-366
44. Tyor W.R., Glass J.D., Griffin J.W., Becker P.S., McArthur J.C., Bezman L., et al. Cytokine expression in the brain during acquired immune deficiency syndrome. Ann Neurol 31 4 (1992) 349-360
45. Conant K., Garzino-Demo A., Nath A., McArthur J.C., Halliday W., Power C., et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci USA 95 (1998) 3117-3121
46. Snyder S.H., and Bredt D.S. Biological roles of nitric oxide. Sci Am 266 5 (1992) 68-71 4-7
47. Heyes M.P., Brew B.B., Martin A., Price R.W., Salazar A., Sidtis J.J., et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol 29 (1991) 202-209
48. Heyes M.P., Rubinow D., Lane C., and Markey S.P. Cerebrospinal fluid quinolinic acid concentrations are increased in acquired immune deficiency syndrome. Ann Neurol 26 (1989) 275-277
49. Nath A., and Geiger J. Neurobiological aspects of human immunodeficiency virus infection: neurotoxic mechanisms. Prog Neurobiol 54 1 (1998) 19-33
50. Genis P., Jett M., Bernton E., Boyle T., Gelbard H., Dzenko K., et al. Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease. J Exp Med 176 (1992) 1703-1718
51. Dawson T.M., Bredt D.S., Fotuhi M., Hwang P.M., and Snyder S.H. Nitric oxide synthase and neuronal NADPH diaphorase are identical in brain and peripheral tissues. Proc Natl Acad Sci USA 88 (1991) 7797-7801
52. Minagar A., Shapshak P., Fujimura R., Ownby R., Heyes M., and Eisdorfer C. The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci 202 1-2 (2002) 13-23
53. Gonzalez-Scarano F., and Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol 5 1 (2005) 69-81
54. Giulian D., Noonan C., and Vaca K. HIV-1 infected mononuclear phagocytes release neurotoxins. Science 250 (1990) 1593-1595
55. Zheng J., Thylin M.R., Cotter R.L., Lopez A.L., Ghorpade A., Persidsky Y., et al. HIV-1 infected and immune competent mononuclear phagocytes induce quantitative alterations in neuronal dendritic arbor: relevance for HIV-1-associated dementia. Neurotoxicol Res 3 (2001) 443-459
56. Xiong H., Zeng Y.C., Zheng J., Thylin M., and Gendelman H.E. Soluble HIV-1 infected macrophage secretory products mediate blockade of long-term potentiation: a mechanism for cognitive dysfunction in HIV-1-associated dementia. J NeuroVirol 5 (1999) 519-528
57. Xiong H., Zeng Y.C., Lewis T., Zheng J., Persidsky Y., and Gendelman H.E. HIV-1 infected mononuclear phagocyte secretory products affect neuronal physiology leading to cellular demise: relevance for HIV-1-associated dementia. J Neurovirol 6 Suppl 1 (2000) S14-S23
58. Yeh M.W., Kaul M., Zheng J., Nottet H.S., Thylin M., Gendelman H.E., et al. Cytokine-stimulated, but not HIV-infected, human monocyte-derived macrophages produce neurotoxic levels of l-cysteine. J Immunol 164 8 (2000) 4265-4270
59. Mattson M. Calcium as sculptor and destroyer of neural circuitry. Exp Gerontol 27 (1992) 29-49
60. Dawson V.L., Dawson T.M., Uhl G.R., and Snyder S.H. Human immunodeficiency virus type 1 coat protein neurotoxicity mediated by nitric oxide in primary cortical cultures. Proc Natl Acad Sci USA 90 (1993) 3256-3259
61. Gelbard H.A., Dzenko K., Diloreto D., Cerro C.D., Cerro M.D., and Epstein L.G. Neurotoxic effects of tumor necrosis factor in primary human neuronal cultures are mediated by activation of the glutamate AMPA recetor subtypes implications for AIDS neuropathogenesis. Dev Neurosci 15 (1993) 417-422
62. Lawrence C.B., Allan S.M., and Rothwell N.J. Interleukin-1beta and the interleukin-1 receptor antagonist act in the striatum to modify excitotoxic brain damage in the rat. Eur J Neurosci 10 3 (1998) 1188-1195
63. Wang P., Barks J.D., and Silverstein F.S. Tat, a human immunodeficiency virus-1-derived protein, augments excitotoxic hippocampal injury in neonatal rats. Neuroscience 88 2 (1999) 585-597
64. Hermann G.E., Rogers R.C., Bresnahan J.C., and Beattie M.S. Tumor necrosis factor-alpha induces cFOS and strongly potentiates glutamate-mediated cell death in the rat spinal cord. Neurobiol Dis 8 4 (2001) 590-599
65. Ma X.C., Gottschall P.E., Chen L.T., Wiranowska M., and Phelps C.P. Role and mechanisms of interleukin-1 in the modulation of neurotoxicity. Neuroimmunomodulation 10 4 (2002) 199-207
66. Xu Y., and Tao Y.X. Involvement of the NMDA receptor/nitric oxide signal pathway in platelet-activating factor-induced neurotoxicity. Neuroreport 15 2 (2004) 263-266
67. Lipton S.A., and Rosenberg P.A. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 330 (1994) 613-622
68. Danbolt N.C. Glutamate uptake. Prog Neurobiol 65 1 (2001) 1-105
69. Arriza J.L., Eliasof S., Kavanaugh M.P., and Amara S.G. Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance. Proc Natl Acad Sci USA 94 8 (1997) 4155-4160
70. Hertz L., Dringen R., Schousboe A., and Robinson S.R. Astrocytes: glutamate producers for neurons. J Neurosci Res 57 4 (1999) 417-428
71. Martinez-Hernandez A., Bell K.P., and Norenberg M.D. Glutamine synthetase: glial localization in brain. Science 195 4284 (1977) 1356-1358
72. Hollmann M., and Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci 17 (1994) 31-108
73. Pin J.P., and Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34 1 (1995) 1-26
74. Monaghan D., Bridges R., and Cotman C. The excitatory amino acid receptors. Annu Rev Pharmacol Toxicol 29 (1989) 365-402
75. Arundine M., and Tymianski M. Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cell Mol Life Sci 61 6 (2004) 657-668
76. Gil Z., and Amitai Y. Adult thalamocortical transmission involves both NMDA and non-NMDA receptors. J Neurophysiol 76 4 (1996) 2547-2554
77. Li X.F., Phillips R., and LeDoux J.E. NMDA and non-NMDA receptors contribute to synaptic transmission between the medial geniculate body and the lateral nucleus of the amygdala. Exp Brain Res 105 1 (1995) 87-100
78. Choi D.W., Koh J.-y., and Peters S. Pharmacology of Glutamate Neuorotoxicity in Cortical Cell Culture: Attenuation by NMDAv Antagonists. J Neurosci 8 1 (1988) 185-196
79. Tymianski M., Charlton M.P., Carlen P.L., and Tator C.H. Source specificity of early calcium neurotoxicity in cultured embryonic spinal neurons. J Neurosci 13 5 (1993) 2085-2104
80. Burnashev N., Monyer H., Seeburg P.H., and Sakmann B. Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit. Neuron 8 1 (1992) 189-198
81. Hollmann M., Hartley M., and Heinemann S. Ca2+ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition. Science 252 5007 (1991) 851-853
82. Kohr G., Melcher T., and Seeburg P.H. Candidate editases for GluR channels in single neurons of rat hippocampus and cerebellum. Neuropharmacology 37 10-11 (1998) 1411-1417
83. Berman F.W., and Murray T.F. Domoic acid neurotoxicity in cultured cerebellar granule neurons is mediated predominantly by NMDA receptors that are activated as a consequence of excitatory amino acid release. J Neurochem 69 2 (1997) 693-703
84. Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 81 3 (1999) 163-221
85. Prehn J.H., Lippert K., and Krieglstein J. Are NMDA or AMPA/kainate receptor antagonists more efficacious in the delayed treatment of excitotoxic neuronal injury?. Eur J Pharmacol 292 2 (1995) 179-189
86. 2+ entry. Neuroreport 6 8 (1995) 1089-1092
87. 2+ entry via AMPA/KA receptors and excitotoxicity in cultured cerebellar Purkinje cells. J Neurosci 14 1 (1994) 187-197
88. Carriedo S.G., Yin H.Z., and Weiss J.H. Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J Neurosci 16 13 (1996) 4069-4079
89. Dingledine R., Borges K., Bowie D., and Traynelis S.F. The glutamate receptor ion channels. Pharmacol Rev 51 1 (1999) 7-61
90. Portera-Cailliau C., Price D.L., and Martin L.J. Non-NMDA and NMDA receptor-mediated excitotoxic neuronal deaths in adult brain are morphologically distinct: further evidence for an apoptosis-necrosis continuum. J Comp Neurol 378 1 (1997) 88-104
91. Ferkany J.W., Zaczek R., and Coyle J.T. Kainic acid stimulates excitatory amino acid neurotransmitter release at presynaptic receptors. Nature 298 5876 (1982) 757-759
92. Anwyl R. Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brain Res Brain Res Rev 29 1 (1999) 83-120
93. Pin J.P., and Acher F. The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Curr Drug Targets CNS Neurol Disord 1 3 (2002) 297-317
94. Lan J.Y., Skeberdis V.A., Jover T., Zheng X., Bennett M.V., and Zukin R.S. Activation of metabotropic glutamate receptor 1 accelerates NMDA receptor trafficking. J Neurosci 21 16 (2001) 6058-6068
95. Gereau R., and Conn P.J. Multiple presynaptic metabotropic glutamate receptors modulate excitatory and inhibitory synaptic transmission in hippocampal area CA1. J Neurosci 15 10 (1995) 6879-6889
96. Nicoletti F., Bruno V., Copani A., Casabona G., and Knopfel T. Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders?. Trends Neurosci 19 7 (1996) 267-271
97. McDonald J.W., Althomsons S.P., Hyrc K.L., Choi D.W., and Goldberg M.P. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nat Med 4 3 (1998) 291-297
98. Olney J.W. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 164 880 (1969) 719-721
99. Coyle J., and Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262 (1993) 689-695
100. Budd S.L., Tenneti L., Lishnak T., and Lipton S.A. Mitochondrial and extramitochondrial apoptotic signaling pathways in cerebrocortical neurons. Proc Natl Acad Sci USA 97 11 (2000) 6161-6166
101. Tenneti L., D'Emilia D.M., Troy C.M., and Lipton S.A. Role of caspases in N-methyl-d-aspartate-induced apoptosis in cerebrocortical neurons. J Neurochem 71 3 (1998) 946-959
102. Ghatan S., Larner S., Kinoshita Y., Hetman M., Patel L., Xia Z., et al. p38 MAP kinase mediates bax translocation in nitric oxide-induced apoptosis in neurons. J Cell Biol 150 2 (2000) 335-347
103. Atlante A., Calissano P., Bobba A., Giannattasio S., Marra E., and Passarella S. Glutamate neurotoxicity, oxidative stress and mitochondria. FEBS Lett 497 1 (2001) 1-5
104. Craven S.E., and Bredt D.S. PDZ proteins organize synaptic signaling pathways. Cell 93 4 (1998) 495-498
105. Bossy-Wetzel E., Schwarzenbacher R., and Lipton S.A. Molecular pathways to neurodegeneration. Nat Med 10 Suppl (2004) S2-S9
106. Watanabe H., and Bannai S. Induction of cysteine transport activity in mouse peritoneal macrophages. J Exp Med 165 (1987) 628-640
107. Schinder A.F., Olson E.C., Spitzer N.C., and Montal M. Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. J Neurosci 16 19 (1996) 6125-6133
108. Fiskum G. Mitochondrial participation in ischemic and traumatic neural cell death. J Neurotrauma 17 10 (2000) 843-855
109. Fiskum G., Starkov A., Polster B.M., and Chinopoulos C. Mitochondrial mechanisms of neural cell death and neuroprotective interventions in Parkinson's disease. Ann N Y Acad Sci 991 (2003) 111-119
110. Bellizzi M.J., Lu S., and Gelbard H.A. Protecting the synapse: evidence for a rational strategy to treat HIV-1 associated neurologic disease. J Neuroimmun Pharmacol 1 1 (2006) 20-31
111. Masliah E., DeTeresa R.M., Mallory M.E., and Hansen L.A. Changes in pathological findings at autopsy in AIDS cases for the last 15 years. AIDS 14 1 (2000) 69-74
112. Garden G.A., Budd S.L., Tsai E., Hanson L., Kaul M., D'Emilia D.M., et al. Caspase cascades in human immunodeficiency virus-associated neurodegeneration. J Neurosci 22 10 (2002) 4015-4024
113. Zheng J., Zhuang W., Yan N., Kou G., Peng H., McNally C., et al. Classification of HIV-1 mediated neuronal dendritic and synaptic damage using multiple criteria linear programming. Neuroinformatics 2 3 (2004) 303-326
114. Park J.S., Bateman M.C., and Goldberg M.P. Rapid alterations in dendrite morphology during sublethal hypoxia or glutamate receptor activation. Neurobiol Dis 3 3 (1996) 215-227
115. Hasbani M.J., Hyrc K.L., Faddis B.T., Romano C., and Goldberg M.P. Distinct roles for sodium, chloride, and calcium in excitotoxic dendritic injury and recovery. Exp Neurol 154 1 (1998) 241-258
116. Swann J.W., Al-Noori S., Jiang M., and Lee C.L. Spine loss and other dendritic abnormalities in epilepsy. Hippocampus 10 5 (2000) 617-625
117. Hasbani M.J., Schlief M.L., Fisher D.A., and Goldberg M.P. Dendritic spines lost during glutamate receptor activation reemerge at original sites of synaptic contact. J Neurosci 21 7 (2001) 2393-2403
118. Mattson M.P., Keller J.N., and Begley J.G. Evidence for synaptic apoptosis. Exp Neurol 153 1 (1998) 35-48
119. Ying W. Deleterious network: a testable pathogenetic concept of Alzheimer's disease. Gerontology 43 4 (1997) 242-253
120. Cotter R., Williams C., Ryan L., Erichsen D., Lopez A., Peng H., et al. Fractalkine (CX3CL1) and brain inflammation: implications for HIV-1-associated dementia. J Neurovirol 8 6 (2002) 585-598
121. Gartner S. HIV infection and dementia. Science 287 5453 (2000) 602-604
122. Zheng J., Thylin M.R., Persidsky Y., Williams C.E., Cotter R.L., Zink W., et al. HIV-1 infected immune competent mononuclear phagocytes influence the pathways to neuronal demise. Neurotoxi Res 3 (2001) 461-484
123. Floden A.M., Li S., and Combs C.K. Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J Neurosci 25 10 (2005) 2566-2575
124. Bellizzi M.J., Lu S.M., Masliah E., and Gelbard H.A. Synaptic activity becomes excitotoxic in neurons exposed to elevated levels of platelet-activating factor. J Clin Invest 115 11 (2005) 3185-3192
125. Viviani B., Bartesaghi S., Gardoni F., Vezzani A., Behrens M.M., Bartfai T., et al. Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J Neurosci 23 25 (2003) 8692-8700
126. Fontana G., Valenti L., and Raiteri M. Gp120 can revert antagonism at the glycine site of NMDA receptors mediating GABA release from cultured hippocampal neurons. J Neurosci Res 49 6 (1997) 732-738
127. Nath A., Haughey N.J., Jones M., Anderson C., Bell J.E., and Geiger J.D. Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann Neurol 47 2 (2000) 186-194
128. Lee S.C., Hatch W.C., Liu W., Brosnan C.F., and Dickson D.W. Productive infection of human fetal microglia in vitro by HIV-1. Ann N Y Acad Sci 693 (1993) 314-316
129. An S.F., Groves M., Giometto B., Beckett A.A., and Scaravilli F. Detection and localisation of HIV-1 DNA and RNA in fixed adult AIDS brain by polymerase chain reaction/in situ hybridisation technique. Acta Neuropathol (Berl) 98 5 (1999) 481-487
130. Bagasra O., Lavi E., Bobroski L., Khalili K., Pestaner J.P., Tawadros R., et al. Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry. AIDS 10 (1996) 573-585
131. Nuovo G.J., Gallery F., MacConnell P., and Braun A. In situ detection of polymerase chain reaction-amplified HIV-1 nucleic acids and tumor necrosis factor-α RNA in teh central nervous system. Am J Pathol 144 (1994) 659-666
132. Ranki A., Nyberg M., Ovod V., Haltia M., Elovaara I., Raininko R., et al. Abundant expression of HIV Nef and Rev proteins in brain astrocytes in vivo is associated with dementia. AIDS 9 (1995) 1001-1008
133. Saito Y., Sharer L.R., Epstein L.G., Michaels J., Mintz M., Louder M., et al. Overexpression of nef as a marker for restricted HIV-1 infection of astrocytes in postmortem pediatric central nervous tissues. Neurology 44 3 Pt. 1 (1994) 474-481
134. Stoler M., Eskin T., Benn S., Angerer R., and Angerer L. Human T-cell lympotropic virus type III infection of the central nervous system. JAMA 256 (1986) 2360-2364
135. Takahashi K., Wesselingh S.L., Griffin D.E., McArthur J.C., Johnson R.T., and Glass J.D. Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Ann Neurol 39 (1996) 705-711
136. Tornatore C., Chandra R., Berger J.R., and Major E.O. HIV-1 infection of subcortical astrocytes in the pediatric central nervous system. Neurology 44 3 Pt 1 (1994) 481-487
137. Dong Y., and Benveniste E.N. Immune function of astrocytes. Glia 36 2 (2001) 180-190
138. Beattie E.C., Stellwagen D., Morishita W., Bresnahan J.C., Ha B.K., Von Zastrow M., et al. Control of synaptic strength by glial TNFalpha. Science 295 5563 (2002) 2282-2285
139. 2+-permeable AMPA receptors in Bergmann glia. Science 292 5518 (2001) 926-929
140. Oliet S.H., Piet R., and Poulain D.A. Control of glutamate clearance and synaptic efficacy by glial coverage of neurons. Science 292 5518 (2001) 923-926
141. Ullian E.M., Sapperstein S.K., Christopherson K.S., and Barres B.A. Control of synapse number by glia. Science 291 5504 (2001) 657-661
142. Danbolt N.C. The high affinity uptake system for excitatory amino acids in the brain. Prog Neurobiol 44 4 (1994) 377-396
143. Nicholls D., and Attwell D. The release and uptake of excitatory amino acids [see comments]. Trends Pharmacol Sci 11 11 (1990) 462-468
144. Tanaka K., Watase K., Manabe T., Yamada K., Watanabe M., Takahashi K., et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276 5319 (1997) 1699-1702
145. Hardin-Pouzet H., Krakowski M., Bourbonniere L., Didier-Bazes M., Tran E., and Owens T. Glutamate metabolism is down-regulated in astrocytes during experimental allergic encephalomyelitis. Glia 20 1 (1997) 79-85
146. Pitt D., Nagelmeier I.E., Wilson H.C., and Raine C.S. Glutamate uptake by oligodendrocytes: implications for excitotoxicity in multiple sclerosis. Neurology 61 8 (2003) 1113-1120
147. Ohgoh M., Hanada T., Smith T., Hashimoto T., Ueno M., Yamanishi Y., et al. Altered expression of glutamate transporters in experimental autoimmune encephalomyelitis. J Neuroimmunol 125 1-2 (2002) 170-178
148. Fine S.M., Angel R.A., Perry S.W., Epstein L.G., Rothstein J.D., Dewhurst S., et al. Tumor necrosis factor α inhibits glutamate uptake by primary human astrocytes. J Biol Chem 271 (1996) 15303-15306
149. Wang Z., Pekarskaya O., Bencheikh M., Chao W., Gelbard H.A., Ghorpade A., et al. Reduced expression of glutamate transporter EAAT2 and impaired glutamate transport in human primary astrocytes exposed to HIV-1 or gp120. Virology 312 1 (2003) 60-73
150. Bezzi P., Carmignoto G., Pasti L., Vesce S., Rossi D., Rizzini B.L., et al. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 391 6664 (1998) 281-285
151. Bezzi P., Domercq M., Brambilla L., Galli R., Schols D., De Clercq E., et al. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci 4 7 (2001) 702-710
152. Madl J.E., and Burgesser K. Adenosine triphosphate depletion reverses sodium-dependent, neuronal uptake of glutamate in rat hippocampal slices. J Neurosci 13 10 (1993) 4429-4444
153. Nicholls D., and Attwell D. The release and uptake of excitatory amino acids. Trends Pharmacol Sci 11 11 (1990) 462-468
154. Stover J.F., Pleines U.E., Morganti-Kossmann M.C., Kossmann T., Lowitzsch K., and Kempski O.S. Neurotransmitters in cerebrospinal fluid reflect pathological activity. Eur J Clin Invest 27 12 (1997) 1038-1043
155. Sarchielli P., Greco L., Floridi A., Floridi A., and Gallai V. Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. Arch Neurol 60 8 (2003) 1082-1088
156. Ferrarese C., Aliprandi A., Tremolizzo L., Stanzani L., De Micheli A., Dolara A., et al. Increased glutamate in CSF and plasma of patients with HIV dementia. Neurology 57 4 (2001) 671-675
157. Dienel G.A., and Hertz L. Astrocytic contributions to bioenergetics of cerebral ischemia. Glia 50 4 (2005) 362-388
158. Tossman U., Jonsson G., and Ungerstedt U. Regional distribution and extracellular levels of amino acids in rat central nervous system. Acta Physiol Scand 127 4 (1986) 533-545
159. Olalla L., Gutierrez A., Campos J.A., Khan Z.U., Alonso F.J., Segura J.A., et al. Nuclear localization of L-type glutaminase in mammalian brain. J Biol Chem 277 41 (2002) 38939-38944
160. Baglietto-Vargas D., Lopez-Tellez J.F., Moreno-Gonzalez I., Gutierrez A., and Aledo J.C. Segregation of two glutaminase isoforms in islets of Langerhans. Biochem J 381 Pt 2 (2004) 483-487
161. Olalla L., Aledo J.C., Bannenberg G., and Marquez J. The C-terminus of human glutaminase L mediates association with PDZ domain-containing proteins. FEBS Lett 488 3 (2001) 116-122
162. Kovacevic Z., and McGivan J.D. Mitochondrial metabolism of glutamine and glutamate and its physiological significance. Physiol Rev 63 2 (1983) 547-605
163. Colquhoun A., and Newsholme E.A. Aspects of glutamine metabolism in human tumour cells. Biochem Mol Biol Int 41 3 (1997) 583-596
164. Medina M.A., Sanchez-Jimenez F., Marquez J., Rodriguez Quesada A., and Nunez de Castro I. Relevance of glutamine metabolism to tumor cell growth. Mol Cell Biochem 113 1 (1992) 1-15
165. Aledo J.C., Segura J.A., Medina M.A., Alonso F.J., Nunez de Castro I., and Marquez J. Phosphate-activated glutaminase expression during tumor development. FEBS Lett 341 1 (1994) 39-42
166. Elgadi K.M., Meguid R.A., Qian M., Souba W.W., and Abcouwer S.F. Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. Physiol Genomics 1 2 (1999) 51-62
167. Szeliga M., Sidoryk M., Matyja E., Kowalczyk P., and Albrecht J. Lack of expression of the liver-type glutaminase (LGA) mRNA in human malignant gliomas. Neurosci Lett 374 3 (2005) 171-173
168. Mock B., Kozak C., Seldin M.F., Ruff N., D'Hoostelaere L., Szpirer C., et al. A glutaminase (gis) gene maps to mouse chromosome 1, rat chromosome 9, and human chromosome 2. Genomics 5 2 (1989) 291-297
169. Levy N., Boettger-Tong H., Dohmae K., Agoulnik A.I., Ty T.I., Nishimune Y., et al. Physical and genetic linkage of glutaminase (Gls), signal transducer and activator of transcription 1 (Stat1), and xeroderma pigmentosum complementation group G (Xpg) on mouse proximal chromosome 1. Genomics 54 2 (1998) 355-356
170. Porter D., Hansen W.R., Taylor L., and Curthoys N.P. Differential expression of multiple glutaminase mRNAs in LLC-PK1-F+ cells. Am J Physiol 269 3 Pt. 2 (1995) F363-F373
171. Porter L.D., Ibrahim H., Taylor L., and Curthoys N.P. Complexity and species variation of the kidney-type glutaminase gene. Physiol Genomics 9 3 (2002) 157-166
172. Shapiro R.A., Haser W.G., and Curthoys N.P. The orientation of phosphate-dependent glutaminase on the inner membrane of rat renal mitochondria. Arch Biochem Biophys 243 1 (1985) 1-7
173. Shapiro R.A., Farrell L., Srinivasan M., and Curthoys N.P. Isolation, characterization, and in vitro expression of a cDNA that encodes the kidney isoenzyme of the mitochondrial glutaminase. J Biol Chem 266 28 (1991) 18792-18796
174. Laake J.H., Takumi Y., Eidet J., Torgner I.A., Roberg B., Kvamme E., et al. Postembedding immunogold labelling reveals subcellular localization and pathway-specific enrichment of phosphate activated glutaminase in rat cerebellum. Neuroscience 88 4 (1999) 1137-1151
175. Rosenberg P.A. Accumulation of extracellular glutamate and neuronal death in astrocyte-poor cortical cultures exposed to glutamine. Glia 4 1 (1991) 91-100
176. Driscoll B.F., Deibler G.E., Law M.J., and Crane A.M. Damage to neurons in culture following medium change: role of glutamine and extracellular generation of glutamate. J Neurochem 61 5 (1993) 1795-1800
177. Newcomb R., Pierce A.R., Kano T., Meng W., Bosque-Hamilton P., Taylor L., et al. Characterization of mitochondrial glutaminase and amino acids at prolonged times after experimental focal cerebral ischemia. Brain Res 813 1 (1998) 103-111
178. Zielke H.R., Tildon J.T., Zielke C.L., Baab P.J., and Landry M.E. Functional intracellular glutaminase activity in intact astrocytes. Neurochem Res 14 4 (1989) 327-332
179. Werner P., Pitt D., and Raine C.S. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 50 2 (2001) 169-180
180. Mena F.V., Baab P.J., Zielke C.L., and Zielke H.R. In vivo glutamine hydrolysis in the formation of extracellular glutamate in the injured rat brain. J Neurosci Res 60 5 (2000) 632-641
181. Piani D., Frei K., Do K., Cuenod M., and Fontana A. Murine brain macrophages induce NMDA receptor mediated neurotoxicity in vitro by secreting glutamate. Neurosci Lett 133 (1991) 159-162
182. Ramonet D., Rodriguez M.J., Fredriksson K., Bernal F., and Mahy N. In vivo neuroprotective adaptation of the glutamate/glutamine cycle to neuronal death. Hippocampus 14 5 (2004) 586-594
183. Muscoli C., Visalli V., Colica C., Nistico R., Palma E., Costa N., et al. The effect of inflammatory stimuli on NMDA-related activation of glutamine synthase in human cultured astroglial cells. Neurosci Lett 373 3 (2005) 184-188
184. Werner P., Pitt D., and Raine C.S. Glutamate excitotoxicity - a mechanism for axonal damage and oligodendrocyte death in Multiple Sclerosis?. J Neural Transm Suppl 60 (2000) 375-385
185. Smith T., Groom A., Zhu B., and Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 6 1 (2000) 62-66
186. Raber J., Toggas S.M., Lee S., Bloom F.E., Epstein C.J., and Mucke L. Central nervous system expression of HIV-1 Gp120 activates the hypothalamic-pituitary-adrenal axis: evidence for involvement of NMDA receptors and nitric oxide synthase. Virology 226 2 (1996) 362-373
187. Anderson E.R., Gendelman H.E., and Xiong H. Memantine protects hippocampal neuronal function in murine human immunodeficiency virus type 1 encephalitis. J Neurosci 24 32 (2004) 7194-7198
188. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., and Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291 3 (2004) 317-324
189. Lipton S.A., and Chen H.S. Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine. Cell Death Differ 1 (2004) 18-20
190. Ellison G. Competitive and non-competitive NMDA antagonists induce similar limbic degeneration. Neuroreport 5 18 (1994) 2688-2692
191. Muir K.W., Grosset D.G., and Lees K.R. Clinical pharmacology of CNS 1102 in man. Ann N Y Acad Sci 765 (1995) 336-337
192. Olney J.W., and Farber N.B. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 13 4 (1995) 335-345
193. Curthoys N.P., and Kuhlenschmidt T. Phosphate-independent glutaminase from rat kidney. Partial purification and identity with gamma-glutamyltranspeptidase. J Biol Chem 250 6 (1975) 2099-2105
194. La Zhao J, Herek S, Curthoys N, Tsukamoto T, Ferraris D, Zheng J. Glutaminase mediated glutamate neurotoxicity by HIV-1 infected macrophage. Washington (DC): Society for Neuroscience; 2005.
195. Kenny J., Bao Y., Hamm B., Taylor L., Toth A., Wagers B., et al. Bacterial expression, purification, and characterization of rat kidney-type mitochondrial glutaminase. Protein Expr Purif 31 1 (2003) 140-148
196. Aledo J.C., Rosado A., Olalla L., Campos J.A., and Marquez J. Overexpression, purification, and characterization of glutaminase-interacting protein, a PDZ-domain protein from human brain. Protein Expr Purif 23 3 (2001) 411-418